BullFrog AI Holdings Inc. has published a presentation outlining its proprietary artificial intelligence and machine learning platform designed for drug discovery and development. The company highlights its advanced data preparation and biologically grounded analytics, which aim to improve clarity and precision in drug development processes where traditional AI solutions may be limited. The platform supports multi-modal analytics, integrating omics, clinical, and real-world data to enable target identification, drug repurposing, and clinical trial optimization. BullFrog AI also notes its scalable and explainable technology, strategic partnerships, and a lean business model with multiple revenue streams. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BullFrog AI Holdings Inc. published the original content used to generate this news brief on January 26, 2026, and is solely responsible for the information contained therein.